price
EY
NASDAQ · EYPT
EyePoint Pharmaceuticals, Inc.
Healthcare · Biotechnology
$2.99
Down-$0.15 (-4.78%)
Updated Oct 19, 2026, 10:31 AM
SID Score
3.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.11B
- P/E ratio
- -5.5
- Dividend yield
- 0.00%
- 52-week range
- $2.93 – $19.11
- Volume
- 2.76M
- Avg. volume
- 1.29M
Price performance · EYPT
EYPT price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 16, 2026
EYPT closed at $2.99 after 20 trading sessions, down 25.62% for the selected period.
- Last close
- $2.99
- Period change
- -25.62%
- Period low
- $2.99
- Period high
- $4.07
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | $3.14 | $3.15 | $2.9512 | $2.99 | 2.76M |
| Oct 15, 2026 | $3.02 | $3.175 | $3.009 | $3.14 | 2.84M |
| Oct 14, 2026 | $3.04 | $3.055 | $2.93 | $3.01 | 3.16M |
| Oct 13, 2026 | $3.30 | $3.315 | $3.06 | $3.07 | 2.52M |
| Oct 12, 2026 | $3.42 | $3.4299 | $3.285 | $3.32 | 1.9M |
| Oct 9, 2026 | $3.44 | $3.5685 | $3.38 | $3.40 | 1.94M |
| Oct 8, 2026 | $3.30 | $3.52 | $3.27 | $3.46 | 3.26M |
| Oct 7, 2026 | $3.15 | $3.42 | $3.08 | $3.32 | 3.02M |
| Oct 6, 2026 | $3.18 | $3.29 | $3.075 | $3.17 | 1.98M |
| Oct 5, 2026 | $3.28 | $3.28 | $3.05 | $3.15 | 2.76M |
| Oct 2, 2026 | $3.31 | $3.31 | $3.10 | $3.25 | 3.11M |
| Oct 1, 2026 | $3.29 | $3.45 | $3.23 | $3.23 | 2.86M |
| Sep 30, 2026 | $3.42 | $3.46 | $3.25 | $3.27 | 3.44M |
| Sep 29, 2026 | $3.31 | $3.50 | $3.2994 | $3.42 | 2.54M |
| Sep 28, 2026 | $3.58 | $3.60 | $3.265 | $3.31 | 3.3M |
| Sep 25, 2026 | $3.65 | $3.705 | $3.555 | $3.62 | 2.25M |
| Sep 24, 2026 | $3.71 | $3.725 | $3.54 | $3.65 | 2.3M |
| Sep 23, 2026 | $4.10 | $4.1818 | $3.705 | $3.72 | 2.02M |
| Sep 22, 2026 | $4.08 | $4.215 | $3.9723 | $4.07 | 4.46M |
| Sep 21, 2026 | $3.87 | $4.10 | $3.80 | $4.02 | 3.86M |
Latest EYPT news
The latest Smart Investors Daily articles mentioning EYPT.
Stock researchCompany · Forecast
Company
Market Activity
Research & News
Loading stock research…